CD33 and acute myeloid leukemia: JNJ-67571244, CD3-CD33 BiTE, was tested in a phase I, dose-escalating trial in R/R AML and high-risk MDS (NCT03915379) that enrolled 68 patients; the trial was completed on March 28th, 2022, but the results have still not been reported.